<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02554396</url>
  </required_header>
  <id_info>
    <org_study_id>PRX100.FDAII</org_study_id>
    <nct_id>NCT02554396</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia</brief_title>
  <official_title>A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 (Aceclidine/Tropicamide) Ophthalmic Topical Formulation in the Treatment of Early to Moderate Presbyopia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Presbyopia Therapies, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Presbyopia Therapies, LLC</source>
  <brief_summary>
    <textblock>
      This is a one-day, randomized, double-masked, single-center evaluation of the efficacy and&#xD;
      safety of PRX-100 ophthalmic solution compared to placebo in 20 subjects (randomized 4:1,&#xD;
      PRX-100:placebo) to evaluate the safety of PRX-100 and the magnitude and duration of effects&#xD;
      on improving near-vision acuity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>binocular assessment of uncorrected near visual acuity</measure>
    <time_frame>day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pupil diameter</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>PRX-100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRX-100 ophthalmic solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>saline solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRX-100</intervention_name>
    <description>ophthalmic solution</description>
    <arm_group_label>PRX-100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>saline ophthalmic solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. be 45-59 years of age of either sex and any race or ethnicity;&#xD;
&#xD;
          2. be able and willing to provide written informed consent and sign HIPAA form prior to&#xD;
             any study procedure being performed;&#xD;
&#xD;
          3. be able and willing to follow all instructions and attend all study visits;&#xD;
&#xD;
          4. have a negative urine pregnancy test at Visit 1, if female of childbearing potential&#xD;
             (those who have experienced menarche and who are not surgically sterilized [bilateral&#xD;
             tubal ligation, hysterectomy or bilateral oophorectomy] or post-menopausal [12 months&#xD;
             after last menses]) and must use adequate birth control throughout the study period.&#xD;
             Adequate birth control is defined as hormonal - oral, implantable, injectable, or&#xD;
             transdermal contraceptives; mechanical - spermicide in conjunction with a barrier such&#xD;
             as condom or diaphragm; intrauterine device (IUD); or surgical sterilization of&#xD;
             partner. For non-sexually active females, abstinence may be regarded as an adequate&#xD;
             method of birth control;&#xD;
&#xD;
          5. be an early to moderate presbyope&#xD;
&#xD;
          6. be able and willing to avoid all disallowed medication(s) for the appropriate washout&#xD;
             period and during the study without significant risk to the subject (see exclusion&#xD;
             15).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. have known contraindications or sensitivity to the use of any of the study&#xD;
             medications(s) or their components;&#xD;
&#xD;
          2. have an active ocular infection (bacterial, viral or fungal), positive history of an&#xD;
             ocular herpetic infection, preauricular lymphadenopathy, or ongoing, active ocular&#xD;
             inflammation (e.g. moderate to severe blepharitis, allergic conjunctivitis, peripheral&#xD;
             ulcerative keratitis, scleritis, uveitis) in either eye. Mild dry eye controlled with&#xD;
             artificial tears and mild blepharitis controlled with lid scrubs is allowed;&#xD;
&#xD;
          3. have had surgical intervention (ocular or systemic) within 6 months prior to Visit 1,&#xD;
             or planned surgical intervention within 30 days thereafter;&#xD;
&#xD;
          4. have had refractive surgery in the past;&#xD;
&#xD;
          5. have dry eye history defined as either current use of Restasis®, past history of&#xD;
             insertion of punctual plugs, or daily use of artificial tears more than one drop per&#xD;
             day;&#xD;
&#xD;
          6. have a known history of retinal detachment, diabetic retinopathy, or progressive&#xD;
             retinal disease;&#xD;
&#xD;
          7. have an intraocular pressure that is less than 5 mmHg or greater than 22 mmHg, or be&#xD;
             on any type of intraocular hypertension or any type of glaucoma topical treatment at&#xD;
             Visit 1;&#xD;
&#xD;
          8. have red-green color blindness confirmed by Ishihara test during baseline procedures;&#xD;
&#xD;
          9. have an inability or refuse to discontinue contact lens wear 7 days prior to the study&#xD;
             visit and during the study visit;&#xD;
&#xD;
         10. have used an investigational drug or device within 30 days of starting the study or be&#xD;
             concurrently enrolled in another investigational drug or device study;&#xD;
&#xD;
         11. be a female of childbearing potential who is currently pregnant, nursing or planning a&#xD;
             pregnancy; tests positive to a urine pregnancy test at Visit 1; or refuses to use an&#xD;
             adequate method of contraception for the duration of the study;&#xD;
&#xD;
         12. have a condition or a situation, which in the Investigator's opinion, may put the&#xD;
             subject at increased risk, confound study data, or interfere significantly with the&#xD;
             subject's study participation, including but not limited to unstable: cardiovascular,&#xD;
             hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic,&#xD;
             hematologic, neurologic, or psychiatric disease;&#xD;
&#xD;
         13. use any of the following disallowed medications during the 2 weeks (14 days) prior to&#xD;
             Visit 1 and during the study:&#xD;
&#xD;
               -  narcotic (opiate class) pain medication (e.g. codeine, oxycontin, Vicodin®,&#xD;
                  Tramadol®)&#xD;
&#xD;
               -  bladder medication (e.g. urecholine, bethanechol®)&#xD;
&#xD;
               -  antipsychotics&#xD;
&#xD;
               -  antidepressants&#xD;
&#xD;
               -  anticholinergics (e.g. atropine, belladonna, benztropine, dicyclomine, donepezil,&#xD;
                  hyoscyamine, propantheline, scopolamine, trihexphenidyl&#xD;
&#xD;
               -  dry mouth (e.g. salagen®), Evoxac®)&#xD;
&#xD;
               -  antihistamines or decongestants&#xD;
&#xD;
               -  artificial tear use of more than 1 drop per day&#xD;
&#xD;
               -  diagnostic medications required by the protocol are allowed;&#xD;
&#xD;
         14. report of recreational drug use (e.g. marijuana, methadone, heroin, cocaine).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Andover Eye Associates</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>September 16, 2015</study_first_submitted>
  <study_first_submitted_qc>September 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2015</study_first_posted>
  <disposition_first_submitted>October 18, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>October 19, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">October 23, 2017</disposition_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ophthalmology</keyword>
  <keyword>vision</keyword>
  <keyword>ocular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

